Association of HLA-B*1502 and*1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 34, Issue 1, 2014, Pages 146-150

  Sun, Dan ^a   Yu, Chun Hua ^a   Liu, Zhi Sheng ^a   He, Xue Lian ^a   Hu, Jia Sheng ^a   Wu, Ge Fei ^a   Mao, Bing ^a   Wu, Shu Hua ^a   Xiang, Hui Hui ^a  

^a Wuhan Children's Hospital   (China)

Author keywords

antiepileptic drugs; children; HLA B*1502; HLA B*1511; Stevens Johnson syndrome

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DRUG DERIVATIVE; HLA B*15:02 ANTIGEN; HLA B15 ANTIGEN; HLA-B*15:02 ANTIGEN; OXCARBAZEPINE; PHENOBARBITAL;

ADOLESCENT; ALLELE; ARTICLE; ASIAN; CHILD; CHINA; ETHNOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; INFANT; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; STEVENS JOHNSON SYNDROME;

ADOLESCENT; ALLELES; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-B15 ANTIGEN; HUMANS; INFANT; MALE; PHENOBARBITAL; POLYMERASE CHAIN REACTION; STEVENS-JOHNSON SYNDROME;

EID: 84894043010     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-014-1247-7     Document Type: Article

References (23)

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. New Engl J Med, 1994,331(19):1272-1285
2. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics, 2006,16(4):297-306
3. Lim KS, Kwan P, Tan CT. Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review. Neurology Asia, 2008,13(6):15-21
4. Chang CC, Too CL, Murad S, et al. Association of HLAB*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol, 2011,50(2):221-224
5. Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLAA*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet, 2011,20(5):1034-1041
6. Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia, 2007,48(5): 1015-1018
7. Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens, 1995,46(5):355-367
8. Lonjou C, Thomas L, Borot N, et al. RegiSCAR Group. A marker for Stevens-Johnson syndrome ethnicity matters. Pharmacogenomics J, 2006,6(4):265-268
9. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004,428(6982):486
10. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia, 2008,49(12):2087-2091
11. Ikeda H, Takahashi Y, Yamazaki E, et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia, 2010,51(2): 297-300
12. Alfirevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics, 2006,7(6):813-818
13. Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol, 2009,75(6):579-582
14. Wu XT, Hu FY, An DM, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients. Epilepsy Behav, 2010,19(3):405-408
15. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia, 2010,51(5):926-930
16. Zhang Y, Wang J, Zhao LM, et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol, 2011,67(9):885-887
17. Wang Q, Zhou JQ, Zhou LM, et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure, 2011,20(6):446-448
18. Shi YW, Min FL, Qin B, et al. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502? Basic Clin Pharmacol Toxicol, 2012,111(1):58-64
19. Kulkantrakorn K, Tassaneeyakul W, Tiamkao S, et al. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract, 2012,12(3):202-208
20. Kaniwa N, Saito Y, Aihara M, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia, 2010,51(12):2461-2465
21. Knowles SR, Shapiro LE, Shear NH. Anticonvulsion hypersensitivity syndrome: incidence, prevention and management. Drug Saf, 1999,21(6):489-501
22. Hirsch LJ, Arif H, Nahm EA, et al. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology, 2008,71(19),1527-1534
23. Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res, 2008,80(23):194-200